Clinical research
Apogenix announced that a new publication in Cancer Management and Research[1] reviews asunercept as a promising treatment option for patients with other malignancies beyond glioblastoma and myelodysplastic syndromes.
uniQure N.V. announced that the planned enrollment of 56 patients has been achieved in the HOPE-B pivotal trial of etranacogene dezaparvovec, an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B.
Hutchison China MediTech Limited has initiated an international Phase I/Ib study of HMPL-689, its novel, highly selective and potent small molecule phosphoinositide-3 kinase delta isoform inhibitor, in patients with relapsed or refractory lymphoma.
Ardelyx said doses of tenapanor, which inhibits controls serum phosphorus by inhibiting the sodium hydrogen exchanger 3 (NHE3), demonstrated a statistically significant reduction in serum phosphorus levels for dialysis patients whose hyperphosphatemia was not previously controlled with phosphate binders alone.
The trials were the PROVE-HF and EVALUATE-HF trials.
AstraZeneca had a big weekend, with positive results from two separate clinical trial programs causing stock to jump 3.4%.
Genentech said Phase III data from the BLOCKSTONE study showed that an individual treated with Xofluza after being exposed to the flu by an infected household member, reduced the risk of developing the flu by 86% compared to placebo.
AbbVie announced that the Phase III MERU trial evaluating Rova-T as first-line maintenance therapy for advanced small-cell lung cancer, failed to demonstrate a survival benefit following a pre-planned interim analysis.
The trials met the primary endpoints, with ofatumumab demonstrating a highly significant and clinically meaningful decrease in the number of confirmed relapses. The trials also hit key secondary endpoints, delaying the time to confirmed disability progression.
Akari Therapeutics, Plc announced financial results for the second quarter ended June 30, 2019 and recent clinical progress.
PRESS RELEASES